USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

  • Cancer Cell Int. 2024 Jul 7;24(1):238. doi: 10.1186/s12935-024-03370-w.
Guo Long  1  2 ,  Dong Wang  3 ,  Jianing Tang  1  2 ,  Kuan Hu  1  2 ,  Ledu Zhou  4  5
Affiliations
  • 1. Department of Liver Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • 2. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • 3. Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
  • 4. Department of Liver Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. [email protected].
  • 5. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. [email protected].
PMID: 38973004 DOI: 10.1186/s12935-024-03370-w
Abstract

Ubiquitination was considered to be a crucial factor in intrahepatic cholangiocarcinoma (iCCA) development. Herein, we identified Ubiquitin-specific peptidase 8 (USP8) as a key regulator for promoting the tumorigenesis of iCCA cell via stabilizing OGT. USP8 was overexpressed in human tumor tissues and correlated with worse survival. Moreover, the mass spectrometry and co-immunoprecipitation analysis indicated that USP8 interacted with OGT. USP8 worked as a bona fide deubiquitylase of OGT. It stabilized OGT in a deubiquitylation activity-dependent manner. Meanwhile, DUB-IN3, the USP8 Inhibitor, could also restrain the malignancy of intrahepatic cholangiocarcinoma. In addition, USP8 depletion promoted the response of iCCA to pemigatinib. In conclusion, our findings pointed to a previously undocumented catalytic role for USP8 as a deubiquitinating enzyme of OGT. The USP8-OGT axis could be a potential target for iCCA therapy.

Keywords
Intrahepatic cholangiocarcinoma; OGT; Pemigatinib; USP8; Ubiquitination.
Products